Literature DB >> 21378384

Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin.

Christoph J Auernhammer1, Burkhard Göke.   

Abstract

Multimodal treatment options for advanced gastroenteropancreatic neuroendocrine tumours (NET) of jejunum/ileum and of pancreatic origin are reviewed. Current topics being discussed are: European Neuroendocrine Tumour Society 2006/7, American Joint Cancer Committee/Union Internationale Contre le Cancer 2009 and WHO 2010 recommendations for grading and staging of NET; surgery of the primary tumour in distant metastasised disease; surgery of metastatic liver disease and impact on survival; somatostatin analogues for symptom control and for tumour control; selective internal radiation therapy with 90Y-microspheres as novel local ablative therapy in liver metastases; peptide receptor radionuclide therapy; novel chemotherapy regimens (eg, temozolomide) and novel targeted therapies (eg, sunitinib and everolimus).

Entities:  

Mesh：

Year:  2011        PMID： 21378384     DOI： 10.1136/gut.2009.204453

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  33 in total

1.  Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin.

Authors:  Wieland H Sommer; Felix Ceelen; Xabier García-Albéniz; Philipp M Paprottka; Christoph J Auernhammer; Marco Armbruster; Konstantin Nikolaou; Alexander R Haug; Maximilian F Reiser; Daniel Theisen
Journal:  Eur Radiol       Date:  2013-06-28       Impact factor: 5.315

Review 2.  Pancreatic neuroendocrine tumors.

Authors:  Shailesh V Shrikhande; Bhawna Sirohi; Mahesh Goel; Savio G Barreto
Journal:  Indian J Gastroenterol       Date:  2012-10-03

Review 3.  Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging.

Authors:  Kyung Won Kim; Katherine M Krajewski; Mizuki Nishino; Jyothi P Jagannathan; Atul B Shinagare; Sree Harsha Tirumani; Nikhil H Ramaiya
Journal:  AJR Am J Roentgenol       Date:  2013-10       Impact factor: 3.959

Review 4.  Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract.

Authors:  Magaly Zappa; Mohamed Abdel-Rehim; Olivia Hentic; Marie-Pierre Vullierme; Philippe Ruszniewski; Valérie Vilgrain
Journal:  Target Oncol       Date:  2012-05-22       Impact factor: 4.493

5.  Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells.

Authors:  Matilde Spampatti; George Vlotides; Gerald Spöttl; Julian Maurer; Burkhard Göke; Christoph J Auernhammer
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 6.  [Neuroendocrine tumors of the duodenum and pancreas. Surgical strategy].

Authors:  L Fischer; A Mehrabi; M W Büchler
Journal:  Chirurg       Date:  2011-07       Impact factor: 0.955

7.  [Surgery for neuroendocrine tumors of the gastroenteropancreatic system (GEP-NET)].

Authors:  P E Goretzki; A Starke; A Akca; B J Lammers
Journal:  Internist (Berl)       Date:  2012-02       Impact factor: 0.743

8.  [Medicinal therapy of metastasized neuroendocrine tumors of the gastroenteropancreatic system.]

Authors:  C J Auernhammer; C Spitzweg; V Heinemann; B Göke
Journal:  Internist (Berl)       Date:  2012-02-02       Impact factor: 0.743

9.  An overview of the surgical management of hepatic neuroendocrine metastases.

Authors:  S Pathak; I Dash; M R Taylor; G J Poston
Journal:  Indian J Surg Oncol       Date:  2012-02-16

10.  Hepatic micrometastases are associated with poor prognosis in patients with liver metastases from neuroendocrine tumors of the digestive tract.

Authors:  William E Gibson; Raul S Gonzalez; Justin M M Cates; Eric Liu; Chanjuan Shi
Journal:  Hum Pathol       Date:  2018-05-12       Impact factor: 3.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.